{"id":21769,"date":"2022-06-29T09:13:11","date_gmt":"2022-06-29T07:13:11","guid":{"rendered":"https:\/\/idibell.cat\/?p=21769"},"modified":"2022-06-29T09:13:40","modified_gmt":"2022-06-29T07:13:40","slug":"un-assaig-clinic-ofereix-resultat-positius-per-al-tractament-dels-limfomes-cutanis-mes-habituals-amb-un-medicament-immunosupressor","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/06\/un-assaig-clinic-ofereix-resultat-positius-per-al-tractament-dels-limfomes-cutanis-mes-habituals-amb-un-medicament-immunosupressor\/","title":{"rendered":"Un assaig cl\u00ednic ofereix resultat positius per al tractament dels limfomes cutanis m\u00e9s habituals amb un medicament immunosupressor"},"content":{"rendered":"<p>La Dra. Cristina Muniesa i el Dr. Octavi Servitje, del Servei de Dermatologia de l\u2019Hospital Universitari de Bellvitge (HUB) i investigadors de l\u2019IDIBELL, han participat en aquest treball que avalua l\u2019\u00fas del pimecrolimus t\u00f2pic en la micosi fungoide i que ha estat publicat a la prestigiosa revista <a href=\"https:\/\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026(22)00107-7\/fulltext?rss=yes\"><em>The Lancet Haematology<\/em><\/a>.<\/p>\n<p>L\u2019assaig multic\u00e8ntric PimTo-MF, de fase 2, ha consistit en l\u2019administraci\u00f3 per via t\u00f2pica de pimecrolimus, un f\u00e0rmac inhibidor de les subst\u00e0ncies que provoquen inflamaci\u00f3, a pacients en les primeres fases d\u2019una micosi fungoide, el tipus m\u00e9s freq\u00fcent de limfoma cutani.<\/p>\n<p>Sis centres hospitalaris, entre ells l\u2019IDIBELL, han participat en l\u2019assaig, que ha registrat uns resultats for\u00e7a positius. M\u00e9s del 50% dels pacients van respondre de forma positiva a l\u2019aplicaci\u00f3 en forma de crema del pimecrolimus i va ser ben tolerat per la pr\u00e0ctica totalitat d\u2019ells.<\/p>\n<p>El pimecrolimus \u00e9s un inhibidor t\u00f2pic de la calcineurina, un enzim responsable de l\u2019activaci\u00f3 de la prote\u00efna que provoca l\u2019estimulaci\u00f3 del creixement i proliferaci\u00f3 dels limf\u00f2cits T. Aquests limf\u00f2cits s\u00f3n els encarregats de coordinar la\u00a0resposta immune mitjan\u00e7ant les c\u00e8l\u00b7lules, aix\u00ed com tamb\u00e9 de funcions de cooperaci\u00f3 necess\u00e0ries perqu\u00e8 es desenvolupin totes les formes de resposta immune. Aquest \u00e9s el primer assaig cl\u00ednic que avalua el tractament del limfoma cutani de c\u00e8l\u00b7lules T amb un inhibidor de la calcineurina.<\/p>\n<p>Els inhibidors t\u00f2pics de la calcineurina ja s\u2019utilitzen per al tractament de la dermatitis at\u00f2pica i d\u2019altres malalties cut\u00e0nies. \u201c<em>Recentment s\u2019ha demostrat que un percentatge variable de pacients amb micosi fungoide presenten mutacions a la via de la calcineurina, fet que ha justificat aquest assaig cl\u00ednic amb pimecrolimus, que obre la possibilitat d\u2019un nou tractament t\u00f2pic efica\u00e7 en pacients amb formes inicials d\u2019aquesta malaltia<\/em>\u201d, conclou el Dr. Octavi Servitje.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Dra. Cristina Muniesa i el Dr. Octavi Servitje, del Servei de Dermatologia de l\u2019Hospital Universitari de Bellvitge (HUB) i investigadors de l\u2019IDIBELL, han participat en aquest treball que avalua l\u2019\u00fas del pimecrolimus t\u00f2pic en la micosi fungoide i que ha estat publicat a la prestigiosa revista The Lancet Haematology<\/p>\n","protected":false},"author":8,"featured_media":21770,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,449],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-07 14:38:10","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21769"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21769"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21769\/revisions"}],"predecessor-version":[{"id":21772,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21769\/revisions\/21772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21770"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}